Citation Impact
Citing Papers
C-RAF Mutations Confer Resistance to RAF Inhibitors
2013
Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
2013 StandoutScience
Combinatorial Treatments That Overcome PDGFRβ-Driven Resistance of Melanoma Cells to V600EB-RAF Inhibition
2011
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
2011
A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition
2013
Copper Chelation Inhibits BRAFV600E-Driven Melanomagenesis and Counters Resistance to BRAFV600E and MEK1/2 Inhibitors
2017
RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models
2010
Identification of the MEK1(F129L) Activating Mutation as a Potential Mechanism of Acquired Resistance to MEK Inhibition in Human Cancers Carrying the B-Raf V600E Mutation
2011
A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors
2014
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
2004 StandoutScience
The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies
2015
BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
2014
Cancer statistics, 2022
2022 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Suppression of Hypoxia-Inducible Factor 2α Restores p53 Activity via Hdm2 and Reverses Chemoresistance of Renal Carcinoma Cells
2009
On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models
2016 StandoutNatureNobel
Hallmarks of Cancer: The Next Generation
2011 Standout
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
2010
Cancer Statistics, 2021
2021 Standout
Trametinib (GSK1120212) in the treatment of melanoma
2013
Efficient T Cell Activation via a Toll-Interleukin 1 Receptor-Independent Pathway
2006 StandoutNobel
Oncology Meets Immunology: The Cancer-Immunity Cycle
2013 Standout
A view on drug resistance in cancer
2019 StandoutNature
Analysis of the genome to personalize therapy for melanoma
2010
Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma
2011
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
2015 Standout
Receptor Interacting Protein Kinase-3 Determines Cellular Necrotic Response to TNF-α
2009 Standout
Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
2011
Tumor adaptation and resistance to RAF inhibitors
2013
The CD95(APO-1/Fas) DISC and beyond
2003
Caspases: pharmacological manipulation of cell death
2005 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors
2004
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
2014 Standout
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
2014 StandoutNature
Cancer drug resistance: an evolving paradigm
2013 Standout
Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning
2018 Standout
Hyaluronan: from extracellular glue to pericellular cue
2004 Standout
Phosphorylation of Bid by Casein Kinases I and II Regulates Its Cleavage by Caspase 8
2001
Radiomics: Images Are More than Pictures, They Are Data
2015 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
2017 Standout
Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer
2013
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
2014
Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer
2014
Indolocarbazole natural products: occurrence, biosynthesis, and biological activity
2006
Pyrrolidinyl‐Spirooxindole Natural Products as Inspirations for the Development of Potential Therapeutic Agents
2007 Standout
Identification of bisindolylmaleimides and indolocarbazoles as inhibitors of HCV replication by tube-capture-RT-PCR
2009
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
2010 StandoutNature
Targeting Mutant BRAF in Melanoma
2012
Regulation of death receptor-mediated apoptosis pathways
2000
Lung cancer: current therapies and new targeted treatments
2016 Standout
Treating ALK-positive lung cancer—early successes and future challenges
2012
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
2010 Nature
Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
2016 Standout
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study
2013
IKK/NF- B signaling: balancing life and death - a new approach to cancer therapy
2005 Standout
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
2015
Inhibiting the p53–MDM2 interaction: an important target for cancer therapy
2003
Differential Modulation of Apoptosis Sensitivity in CD95 Type I and Type II Cells
1999
p53 in health and disease
2007 Standout
Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases
2014
Common pitfalls in preclinical cancer target validation
2017 StandoutNobel
Mitochondrial Membrane Permeabilization in Cell Death
2007 Standout
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
2013
Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer
2012
Death and anti-death: tumour resistance to apoptosis
2002 Standout
Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance
2014
Molecular signals in anti-apoptotic survival pathways
2001
Molecular mechanisms of caspase regulation during apoptosis
2004 Standout
The CD95 Type I/Type II model
2003
High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal
2005 Standout
Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: Clinical and Preclinical Data
2015
Targeting autophagy in cancer
2017 Standout
Anaplastic lymphoma kinase as a therapeutic target
2012
A new era in functional genomics screens
2021
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
2010 Standout
Crizotinib in the Treatment of Non–Small-Cell Lung Cancer
2013
The PI3K Pathway in Human Disease
2017 Standout
Acquired resistance to TKIs in solid tumours: learning from lung cancer
2014
Delivery of bioactive molecules into the cell: the Trojan horse approach
2004
Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition
2017
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
MEK Inhibition in the Treatment of Advanced Melanoma
2013
Molecular characterization of pulmonary sarcomatoid carcinoma: analysis of 33 cases
2016
Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies
2014
3d Transition Metals for C–H Activation
2018 Standout
Catalytic Asymmetric Dearomatizing Redox Cross Coupling of Ketones with Aryl Hydrazines Giving 1,4-Diketones
2015 StandoutNobel
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
The MAPK pathway across different malignancies: A new perspective
2014 Standout
ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
2014
Asymmetric Dearomatizing Spirolactonization of Naphthols Catalyzed by Spirobiindane-Based Chiral Hypervalent Iodine Species
2013
Intratumor Heterogeneity: Seeing the Wood for the Trees
2012
Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine
2015
Targeting ALK: Precision Medicine Takes on Drug Resistance
2017
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Occurrence, Biogenesis, and Synthesis of Biologically Active Carbazole Alkaloids
2012 Standout
Targeted therapies for treatment of non‐small cell lung cancer—Recent advances and future perspectives
2015
BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation
2010
Alk Inhibitor Ap26113 in Patients with Advanced Malignancies, Including Alk+ Non-Small Cell Lung Cancer (Nsclc): Updated Efficacy and Safety Data
2014
Copper induces cell death by targeting lipoylated TCA cycle proteins
2022 StandoutScience
Inhibitors of the anaplastic lymphoma kinase
2012
The STRING database in 2023: protein–protein association networks and functional enrichment analyses for any sequenced genome of interest
2022 Standout
Understanding Melanoma Signaling Networks as the Basis for Molecular Targeted Therapy
2009
ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer
2013
Cancer Genome Landscapes
2013 StandoutScience
Differential sensitivity of melanoma cell lines with BRAF V600E mutation to the specific Raf inhibitor PLX4032
2010
Advances in Synthetic Applications of Hypervalent Iodine Compounds
2016 Standout
A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle
2010 StandoutNobel
Applications of Palladium-Catalyzed C–N Cross-Coupling Reactions
2016 Standout
ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it.
2014
Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure
2007
Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.
2015
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922
2015
Works of Lisa Drew being referenced
Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
2008
Mitigation of cardiovascular toxicity in a series of CSF-1R inhibitors, and the identification of AZD7507
2013
Inhibition of the protein kinase C pathway promotes anti-CD95-induced apoptosis in Jurkat T cells
1998
The bisindolylmaleimide protein kinase C inhibitor, Ro 32-2241, reverses multidrug resistance in KB tumour cells
1999
3-Amido-4-anilinocinnolines as a novel class of CSF-1R inhibitor
2011
Fas-mediated apoptosis is dependent on wild-type p53 status in human cancer cells expressing a temperature-sensitive p53 mutant alanine-143.
2003
The CUL5 ubiquitin ligase complex mediates resistance to CDK9 and MCL1 inhibitors in lung cancer cells
2019
Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells
2001
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
2012